MTOR and renal cell adenocarcinoma: In this study, we show that NR4A1 is also expressed and exhibits pro-oncogenic activity in ACHN and 786-O kidney cancer cell lines and treatment with DIM-C-pPhOH and related NR4A1 antagonists inhibit cell growth and mTOR signaling, induce apoptosis and cellular stress (Fig 1A), suggesting that NR4A1 is a potential novel drug target for treating RCC patients that overexpress this receptor.